Literature DB >> 16982731

EPHB4 and survival of colorectal cancer patients.

Veronica Davalos1, Higinio Dopeso, Julio Castaño, Andrew J Wilson, Felip Vilardell, Jordi Romero-Gimenez, Eloy Espín, Manel Armengol, Gabriel Capella, John M Mariadason, Lauri A Aaltonen, Simo Schwartz, Diego Arango.   

Abstract

The family of receptor tyrosine kinases EPH and their Ephrin ligands regulate cell proliferation, migration, and attachment. An important role in colorectal carcinogenesis is emerging for some of its members. In this study, we evaluate the role of EPHB4 in colorectal cancer and its value as a prognostic marker. EPHB4 levels were assessed by immunohistochemical staining of tissue microarrays of 137 colorectal tumors and aberrant hypermethylation of the EPHB4 promoter was investigated using methylation-specific PCR. We found that EPHB4 expression is frequently reduced or lost in colorectal tumors. Patients with low EPHB4 tumor levels had significantly shorter survival than patients in the high EPHB4 group (median survival, 1.8 and >9 years, respectively; P < 0.01, log-rank test), and this finding was validated using an independent set of 125 tumor samples. In addition, we show that EPHB4 promoter hypermethylation is a common mechanism of EPHB4 inactivation. Moreover, reintroduction of EPHB4 resulted in a significant reduction in the clonogenic potential of EPHB4-deficient cells, whereas abrogation of EPHB4 in cells with high levels of this receptor lead to a significant increase in clonogenicity. In summary, we identified EPHB4 as a useful prognostic marker for colorectal cancer. In addition, we provide mechanistic evidence showing that promoter methylation regulates EPHB4 transcription and functional evidence that EPHB4 can regulate the long-term clonogenic potential of colorectal tumor cells, revealing EPHB4 as a potential new tumor suppressor gene in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982731     DOI: 10.1158/0008-5472.CAN-05-4640

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Cancer cells exploit the Eph-ephrin system to promote invasion and metastasis: tales of unwitting partners.

Authors:  Bingcheng Wang
Journal:  Sci Signal       Date:  2011-05-31       Impact factor: 8.192

2.  EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion.

Authors:  Arend H Sikkema; Wilfred F A den Dunnen; Esther Hulleman; Dannis G van Vuurden; Guillermo Garcia-Manero; Hui Yang; Frank J G Scherpen; Kim R Kampen; Eelco W Hoving; Willem A Kamps; Sander H Diks; Maikel P Peppelenbosch; Eveline S J M de Bont
Journal:  Neuro Oncol       Date:  2012-06-21       Impact factor: 12.300

Review 3.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

Review 4.  Regulation and misregulation of Eph/ephrin expression.

Authors:  Dina N Arvanitis; Alice Davy
Journal:  Cell Adh Migr       Date:  2012-03-01       Impact factor: 3.405

Review 5.  Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis.

Authors:  Ombretta Salvucci; Giovanna Tosato
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

6.  Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.

Authors:  Shao-Qing Kuang; Hao Bai; Zhi-Hong Fang; Gonzalo Lopez; Hui Yang; Weigang Tong; Zack Z Wang; Guillermo Garcia-Manero
Journal:  Blood       Date:  2010-01-08       Impact factor: 22.113

7.  KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors.

Authors:  Jamie L McCall; Drew Gehring; Beth K Clymer; Kurt W Fisher; Binita Das; David L Kelly; Hyunseok Kim; Michael A White; Robert E Lewis
Journal:  Mol Cell Biol       Date:  2016-08-12       Impact factor: 4.272

Review 8.  Personalized cancer medicine--advances and socio-economic challenges.

Authors:  David B Jackson; Anil K Sood
Journal:  Nat Rev Clin Oncol       Date:  2011-10-11       Impact factor: 66.675

9.  Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.

Authors:  Whitney A Spannuth; Lingegowda S Mangala; Rebecca L Stone; Amy R Carroll; Masato Nishimura; Mian M K Shahzad; Sun-Joo Lee; Myrthala Moreno-Smith; Alpa M Nick; Ren Liu; Nicholas B Jennings; Yvonne G Lin; William M Merritt; Robert L Coleman; Pablo E Vivas-Mejia; Yue Zhou; Valery Krasnoperov; Gabriel Lopez-Berestein; Parkash S Gill; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

Review 10.  Eph receptor tyrosine kinases in cancer stem cells.

Authors:  Jin Chen; Wenqiang Song; Katherine Amato
Journal:  Cytokine Growth Factor Rev       Date:  2014-05-17       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.